Rye Brook Capital LLC sold out of iShares Biotechnology ETF (IBB 2.19%), liquidating 24,270 shares in an estimated $3.50 million trade based on quarterly average pricing, according to a new SEC filing.
What happened
According to a SEC filing dated January 26, 2026, Rye Brook Capital LLC sold its entire holding of 24,270 shares in iShares Biotechnology ETF. The estimated transaction value is $3.50 million, calculated using the average share price during the quarter. The quarter-end position value declined by $3.50 million. The fund reported no remaining shares post-trade.
What else to know
- Rye Brook Capital fully exited IBB.
- Top holdings after the filing:
- NASDAQ: QQQ: $26.14 million (24% of AUM)
- TSX: U-UN.TO: $15.2 million (14% of AUM)
- NASDAQ: SMH: $12.07 million (11% of AUM)
- NYSEMKT: KWEB: $8.01 million (7.5% of AUM)
- NYSE: NXE: $7.12 million (6.6% of AUM)
- As of January 26, 2026, shares were priced at $175.85, up 27.4% over the past year, with 14.48 percentage points of alpha versus the S&P 500
- The position was 1.8% of the fund's AUM in the previous quarter
ETF overview
| Metric | Value |
|---|---|
| AUM | $3.34 billion |
| Price (as of market close January 26, 2026) | $175.85 |
| Dividend yield | 0.23% |
| 1-year total return | 28.42% |
ETF snapshot
- The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed biotechnology stocks, aiming to provide exposure to companies engaged in biotech research, development, and production.
- The fund's portfolio consists primarily of equity securities of biotechnology firms, with at least 80% of assets invested in index components and up to 20% allocated to derivatives and cash equivalents.
- Structured as a non-diversified ETF.
The iShares Biotechnology ETF offers targeted access to the U.S. biotechnology sector, providing investors with a liquid vehicle to participate in the industry's growth and innovation. The fund's strategy emphasizes broad exposure to leading biotech companies, balancing established names with emerging innovators. Its scale and index-based approach enable efficient sector allocation for portfolio managers seeking specialized healthcare exposure.
What this transaction means for investors
Rye Brook Capital’s complete exit from IBB, rather than a partial position trim, signals a decisive shift in the firm's biotech sector allocation. Complete liquidations by institutional investors typically indicate a fundamental change in investment thesis rather than routine portfolio rebalancing. Such moves can reflect concerns about valuation after strong rallies, sector rotation into opportunities elsewhere, or anticipation of headwinds that could reverse recent gains.
The biotech sector experienced a dramatic 2025 turnaround driven by merger and acquisition activity, with major pharmaceutical companies aggressively pursuing smaller firms to refill drug pipelines. IBB rode that rally, up 28% in the last year. Institutional exits during strong performance often suggest profit-taking or skepticism that current valuations reflect future fundamentals.
IBB is best suited for risk-tolerant growth investors who believe the biotech M&A momentum will continue and can weather biotech's notorious volatility. The ETF’s market-cap weighting toward established, cash-flow positive biotech giants offers more stability than equal-weighted alternatives, offering diversified sector exposure without individual stock risk. Because the sector swings so dramatically on clinical trial results, FDA decisions, and M&A speculation, conservative investors should avoid this one.
